Rhodes J, Thomas G, Evans B K
Department of Gastroenterology, University Hospital of Wales, Cardiff.
Drugs. 1997 Feb;53(2):189-94. doi: 10.2165/00003495-199753020-00001.
This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent reviews of current practice which we do not attempt to repeat, nor do we give a comprehensive set of references, but cite well referenced reviews where necessary. New therapeutic developments should ideally stem from an understanding of the cause of pathogenesis of a condition; alternatively, established therapies may be modified or used as a basis for progress. Since the causes of both ulcerative colitis and Crohn's disease remain unknown, most forward thinking on drug development must come from current practice, but remain open to novel approaches. Our thoughts on possible future treatments for inflammatory bowel disease are somewhat selective, and because of their speculative nature are unlikely to coincide with those of others-only the future will reveal genuine advances as they become incorporated into established practice.
本文旨在激发思考，并聚焦于我们认为在炎症性肠病药物治疗方面可能取得进展的领域。尽管在认为与未来发展相关之处会考虑当前的实践情况，但本文并非对当前实践的详尽综述。已有几篇关于当前实践的优秀综述，我们既不试图重复，也不给出一套全面的参考文献，而是在必要时引用参考文献丰富的综述。理想情况下，新的治疗进展应源于对某种疾病发病机制原因的理解；或者，已有的治疗方法可能会被改进或用作进展的基础。由于溃疡性结肠炎和克罗恩病的病因仍然不明，大多数关于药物研发的前瞻性思考必须来自当前的实践，但也要对新方法持开放态度。我们对炎症性肠病未来可能治疗方法的思考有些具有选择性，并且由于其推测性，不太可能与其他人的想法一致——只有未来才能揭示真正的进展，因为它们会被纳入既定的实践中。
